CN1218936C - 甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法 - Google Patents
甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法 Download PDFInfo
- Publication number
- CN1218936C CN1218936C CNB028105974A CN02810597A CN1218936C CN 1218936 C CN1218936 C CN 1218936C CN B028105974 A CNB028105974 A CN B028105974A CN 02810597 A CN02810597 A CN 02810597A CN 1218936 C CN1218936 C CN 1218936C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- phenyl
- coo
- alkenyl
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/54—Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
Description
实施例 | A | R1* | R2 | R3 | R4 | R6 | R5 | 酰胺** | R7 | R8*** | MS**** |
259 | 苯基-2-Cl-4-F | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-NHCOO-CH2-Ph | ok |
260 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-NHCOO-CH2-Ph | ok |
261 | 苯基-2-Cl-4-F | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | CH3 | CH3 | ok |
262 | 苯基-2,4-Cl2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | CH3 | CH3 | ok |
263 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | CH3 | ok |
264 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | CH3 | CH3 | ok |
265 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)2-NHCO-CH3 | ok |
266 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-NH2TFA | ok |
267 | 苯基-2-Cl-4,5-F2 | H | H | 2-Cl | 3-H | 5-H | 6-H | 4 | H | CH3 | ok |
268 | 苯基-2-Cl-4,5-F2 | H | H | 2-Cl | 3-H | 5-H | 6-H | 4 | CH3 | CH3 | ok |
269 | 苯基-2-Cl-4,5-F2 | H | H | 2-Cl | 3-H | 5-H | 6-H | 4 | H | H | ok |
270 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-N(CH3)2TFA | ok |
271 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)2-N(CH3)2TFA | ok |
272 | 苯基-2,4-Cl2 | H | H | 2-Cl | 3-H | 5-H | 6-H | 4 | H | (CH2)2-NHCOO-CH2-CH=CH2 | ok |
273 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)4-NH2TFA | ok |
274 | 苯基-2,4-Cl2 | H | H | 2-Cl | 3-H | 5-H | 6-H | 4 | H | (CH2)2-NH2TFA | ok |
275 | 苯基-2-Cl-4-F | H | H | 2-OCH3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-NH2TFA | ok |
实施例 | A | R1* | R2 | R3 | R4 | R6 | R5 | 酰胺** | R7 | R8*** | MS**** |
276 | 苯基-2-Cl-4,5-F2 | H | H | 3-H | 4-H | 5-COOH | 6-H | 2 | H | CH3 | ok |
277 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | CH3 | ok |
278 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | CH3 | CH3 | ok |
279 | 苯基-2-Cl-4,5-F2 | H | H | 3-H | 4-H | 5-H | 6-H | 2 | H | H | ok |
280 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | CH2-COO-CH3 | ok |
281 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | CH3 | CH2-COO-CH3 | ok |
282 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | (CH2)2-COO-CH3 | ok |
283 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-COO-CH3 | ok |
284 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | CH2-COOH | ok |
285 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | CH3 | CH2-COOH | ok |
286 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | (CH2)2-COOH | ok |
287 | 苯基-2-Cl-4,5-F2 | H | H | 2-OCF3 | 3-H | 5-H | 6-H | 4 | H | (CH2)3-COOH | ok |
实施例 | 在10μM下的抑制率% |
1 | 87 |
2 | 73 |
3 | 75 |
4 | 79 |
5 | 77 |
12 | 92 |
20 | 35 |
29 | 78 |
30 | 76 |
31 | 86 |
41 | 50 |
44 | 11 |
46 | 36 |
47 | 46 |
49 | 13 |
51 | 36 |
53 | 22 |
60 | 36 |
70 | 86 |
75 | 41 |
80 | 50 |
84 | 44 |
89 | 90 |
90 | 34 |
100 | 78 |
101 | 93 |
102 | 14 |
106 | 35 |
111 | 88 |
112 | 100 |
116 | 100 |
117 | 99 |
118 | 70 |
119 | 97 |
120 | 40 |
122 | 12 |
128 | 95 |
147 | 88 |
149 | 76 |
Claims (10)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10125567.5 | 2001-05-25 | ||
DE10125567A DE10125567B4 (de) | 2001-05-25 | 2001-05-25 | Carbonamid substituierte Phenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10207369.4 | 2002-02-21 | ||
DE10207369A DE10207369A1 (de) | 2002-02-21 | 2002-02-21 | Carbonamid substituierte Phenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1525955A CN1525955A (zh) | 2004-09-01 |
CN1218936C true CN1218936C (zh) | 2005-09-14 |
Family
ID=26009397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028105974A Expired - Fee Related CN1218936C (zh) | 2001-05-25 | 2002-05-11 | 甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法 |
Country Status (26)
Country | Link |
---|---|
US (2) | US6812250B2 (zh) |
EP (1) | EP1404650B1 (zh) |
JP (1) | JP4167592B2 (zh) |
KR (1) | KR20040003007A (zh) |
CN (1) | CN1218936C (zh) |
AR (1) | AR036029A1 (zh) |
AT (1) | ATE386017T1 (zh) |
AU (1) | AU2002344151B2 (zh) |
BG (1) | BG108318A (zh) |
BR (1) | BR0210008A (zh) |
CA (1) | CA2448023A1 (zh) |
CZ (1) | CZ20033200A3 (zh) |
DE (1) | DE50211685D1 (zh) |
EE (1) | EE200300581A (zh) |
HK (1) | HK1065027A1 (zh) |
HR (1) | HRP20030971A2 (zh) |
HU (1) | HUP0400052A3 (zh) |
IL (1) | IL159031A0 (zh) |
MX (1) | MXPA03009840A (zh) |
NO (1) | NO20035220D0 (zh) |
NZ (1) | NZ529697A (zh) |
PE (1) | PE20021091A1 (zh) |
PL (1) | PL363871A1 (zh) |
RU (1) | RU2291858C2 (zh) |
SK (1) | SK14442003A3 (zh) |
WO (1) | WO2002096864A1 (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US7223796B2 (en) | 2002-04-11 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use |
DE10215907A1 (de) * | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
CA2493373A1 (en) * | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
US7262220B2 (en) | 2002-07-11 | 2007-08-28 | Sanofi-Aventis Deutschland Gmbh | Urea- and urethane-substituted acylureas, process for their preparation and their use |
EP1523475B1 (de) * | 2002-07-12 | 2009-12-23 | Sanofi-Aventis Deutschland GmbH | Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
DE10302452B4 (de) * | 2003-01-23 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10306502B4 (de) * | 2003-02-17 | 2005-03-17 | Aventis Pharma Deutschland Gmbh | Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel |
US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
US7173151B2 (en) | 2003-02-27 | 2007-02-06 | Sanofi-Aventisdeutschand Gmbh | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
DE10309929B4 (de) * | 2003-03-07 | 2006-02-23 | Sanofi-Aventis Deutschland Gmbh | Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
DE10335092B3 (de) * | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung |
JP2007502283A (ja) * | 2003-08-13 | 2007-02-08 | アムジェン インコーポレイテッド | メラニン凝集ホルモン受容体アンタゴニスト |
US7241787B2 (en) | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
US7795448B2 (en) | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
AU2006250354A1 (en) * | 2005-05-23 | 2006-11-30 | Japan Tobacco Inc. | Pyrazole compound and therapeutic agent for diabetes comprising the same |
DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US8375455B2 (en) | 2006-08-10 | 2013-02-12 | Wayne Odom | System, method, and device for storing and delivering data |
US20080045289A1 (en) * | 2006-08-10 | 2008-02-21 | Wayne Odom | System and device for conducting a game of chance |
WO2008062739A1 (fr) * | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles et leur utilisation en tant que médicaments |
US8634162B2 (en) * | 2007-03-08 | 2014-01-21 | HGST Netherlands B.V. | Perpendicular write head having a stepped flare structure and method of manufacture thereof |
DE102007012284A1 (de) | 2007-03-16 | 2008-09-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
CL2008000979A1 (es) * | 2007-04-11 | 2008-10-17 | Sumitomo Chemical Co | Proceso para producir un compuesto derivado de 2-piridin-2-il-2h-pirazol-3-fenilamida; compuestos intermediarios; el compuesto en si; composicion plaguicida que contiene a dicho compuesto; uso de dicho compuesto como plaguicida; y metodo para control |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102007035334A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102007042154A1 (de) | 2007-09-05 | 2009-03-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
FR2930552B1 (fr) * | 2008-04-24 | 2012-10-12 | Centre Nat Rech Scient | N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog |
US8844054B2 (en) | 2012-04-06 | 2014-09-23 | Wayne Odom | System, method, and device for communicating and storing and delivering data |
US8572720B1 (en) | 2013-05-20 | 2013-10-29 | Wayne Odom | System, method, and device for communicating and storing and delivering data |
US9378339B2 (en) | 2012-04-06 | 2016-06-28 | Wayne Odom | System, method, and device for delivering communications and storing and delivering data |
US8677510B2 (en) | 2012-04-06 | 2014-03-18 | Wayne Odom | System, method, and device for communicating and storing and delivering data |
US8448236B1 (en) | 2012-12-07 | 2013-05-21 | Wayne Odom | System, method, and device for storing and delivering data |
US9043934B2 (en) | 2012-04-06 | 2015-05-26 | Wayne Odom | System, method, and device for delivering communications and storing and delivering data |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA793186B (en) | 1978-07-06 | 1981-02-25 | Duphar Int Res | New urea and thiourea compounds, method of preparing the new compounds, as well as insecticidal compositions on the basis of these compounds |
EP0136745B1 (en) | 1983-09-01 | 1989-06-07 | Duphar International Research B.V | Benzoyl urea derivatives having anti-tumor activity |
ATE40111T1 (de) | 1984-07-05 | 1989-02-15 | Duphar Int Res | Benzoylharnstoffverbindungen sowie solche enthaltende insektizide und akarizide zusammensetzungen. |
CZ220498A3 (cs) | 1996-01-17 | 1998-11-11 | Novo Nordisk A/S | Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití |
DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
RU2200161C2 (ru) | 1996-12-31 | 2003-03-10 | Др. Редди'З Рисерч Фаундейшн | Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение |
KR20010021936A (ko) | 1997-07-16 | 2001-03-15 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용 |
TWI234557B (en) * | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
DK1294682T3 (da) * | 2000-06-09 | 2004-08-02 | Aventis Pharma Gmbh | Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel |
-
2002
- 2002-05-03 PE PE2002000376A patent/PE20021091A1/es not_active Application Discontinuation
- 2002-05-11 BR BR0210008-8A patent/BR0210008A/pt not_active IP Right Cessation
- 2002-05-11 DE DE50211685T patent/DE50211685D1/de not_active Expired - Lifetime
- 2002-05-11 CN CNB028105974A patent/CN1218936C/zh not_active Expired - Fee Related
- 2002-05-11 KR KR10-2003-7015334A patent/KR20040003007A/ko not_active Application Discontinuation
- 2002-05-11 CA CA002448023A patent/CA2448023A1/en not_active Abandoned
- 2002-05-11 AU AU2002344151A patent/AU2002344151B2/en not_active Ceased
- 2002-05-11 EE EEP200300581A patent/EE200300581A/xx unknown
- 2002-05-11 AT AT02774016T patent/ATE386017T1/de not_active IP Right Cessation
- 2002-05-11 MX MXPA03009840A patent/MXPA03009840A/es active IP Right Grant
- 2002-05-11 SK SK1444-2003A patent/SK14442003A3/sk unknown
- 2002-05-11 EP EP02774016A patent/EP1404650B1/de not_active Expired - Lifetime
- 2002-05-11 HU HU0400052A patent/HUP0400052A3/hu unknown
- 2002-05-11 RU RU2003137222/04A patent/RU2291858C2/ru not_active IP Right Cessation
- 2002-05-11 JP JP2003500044A patent/JP4167592B2/ja not_active Expired - Fee Related
- 2002-05-11 NZ NZ529697A patent/NZ529697A/en unknown
- 2002-05-11 CZ CZ20033200A patent/CZ20033200A3/cs unknown
- 2002-05-11 IL IL15903102A patent/IL159031A0/xx unknown
- 2002-05-11 PL PL02363871A patent/PL363871A1/xx not_active Application Discontinuation
- 2002-05-11 WO PCT/EP2002/005205 patent/WO2002096864A1/de active IP Right Grant
- 2002-05-23 AR ARP020101919A patent/AR036029A1/es unknown
- 2002-05-24 US US10/153,597 patent/US6812250B2/en not_active Expired - Lifetime
-
2003
- 2003-11-05 BG BG108318A patent/BG108318A/xx unknown
- 2003-11-24 HR HR20030971A patent/HRP20030971A2/xx not_active Application Discontinuation
- 2003-11-24 NO NO20035220A patent/NO20035220D0/no not_active Application Discontinuation
-
2004
- 2004-10-14 HK HK04107930A patent/HK1065027A1/xx not_active IP Right Cessation
- 2004-11-01 US US10/978,674 patent/US20050143456A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2291858C2 (ru) | 2007-01-20 |
EE200300581A (et) | 2004-02-16 |
JP4167592B2 (ja) | 2008-10-15 |
CN1525955A (zh) | 2004-09-01 |
HUP0400052A2 (hu) | 2004-04-28 |
HRP20030971A2 (en) | 2005-08-31 |
ATE386017T1 (de) | 2008-03-15 |
US6812250B2 (en) | 2004-11-02 |
MXPA03009840A (es) | 2004-04-02 |
HUP0400052A3 (en) | 2008-12-29 |
KR20040003007A (ko) | 2004-01-07 |
AR036029A1 (es) | 2004-08-04 |
BR0210008A (pt) | 2004-08-10 |
PL363871A1 (en) | 2004-11-29 |
US20050143456A1 (en) | 2005-06-30 |
JP2004529194A (ja) | 2004-09-24 |
SK14442003A3 (sk) | 2004-05-04 |
PE20021091A1 (es) | 2003-02-04 |
NZ529697A (en) | 2005-12-23 |
US20030176497A1 (en) | 2003-09-18 |
IL159031A0 (en) | 2004-05-12 |
WO2002096864A1 (de) | 2002-12-05 |
NO20035220D0 (no) | 2003-11-24 |
RU2003137222A (ru) | 2005-05-20 |
CA2448023A1 (en) | 2002-12-05 |
HK1065027A1 (en) | 2005-02-08 |
EP1404650A1 (de) | 2004-04-07 |
EP1404650B1 (de) | 2008-02-13 |
CZ20033200A3 (cs) | 2004-02-18 |
AU2002344151B2 (en) | 2007-01-18 |
BG108318A (en) | 2005-01-31 |
DE50211685D1 (de) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1218936C (zh) | 甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法 | |
CN1280266C (zh) | 酰基苯基脲衍生物,其制备方法和作为药物的用途 | |
CN1286805C (zh) | 酰基-4-羧基苯基脲衍生物、其制备方法及用途 | |
CN1281606C (zh) | 含氮杂环化合物 | |
CN1043531C (zh) | 嘧啶衍生物及其制备方法和用途 | |
CN1478076A (zh) | Mch拮抗剂及它们在治疗肥胖症方面的用途 | |
CN1889960A (zh) | 用于功能上影响不同类型的细胞和用于治疗免疫、炎症、神经和其他疾病的新的二肽基肽酶iv抑制剂 | |
CN1960989A (zh) | 取代的噁唑-苯并异噻唑二氧化物衍生物、其制备方法以及其应用 | |
CN101080382A (zh) | 羟基联苯基羧酸和衍生物其制备方法以及它们的用途 | |
CN1671672A (zh) | 芳基取代的苯并咪唑类及其作为钠通道阻滞剂的用途 | |
CN1325380A (zh) | 苯衍生物和它们的药物用途 | |
CN1423640A (zh) | 在8a位被取代的8,8a-二氢茚并[1,2-d]噻唑衍生物、它们的制备方法和它们作为药物、例如减食欲剂的用途 | |
CN1376063A (zh) | 环胺ccr3拮抗剂 | |
CN1829715A (zh) | 取代的噻唑-苯并异噻唑二氧化物衍生物、其制备方法和其用途 | |
CN1384827A (zh) | 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途 | |
CN1406234A (zh) | 在2-位携带具有磺酰胺结构或砜结构的取代基的8,8a-二氢茚并[1,2-d]噻唑衍生物、它们的制备方法和它们作为药物的用途 | |
CN1232398A (zh) | Il-8受体拮抗剂 | |
CN1910181A (zh) | 杂环基取代的7-氨基-4-喹诺酮-3-甲酸衍生物、其生产方法及其作为药物的用途 | |
CN1659137A (zh) | N-苯甲酰基脲基肉桂酸衍生物、其制备方法及其用途 | |
CN1104017A (zh) | 取代的(芳烷氧基苄基)氨基丙酰胺衍生物及其制备方法 | |
CN1294578A (zh) | 新的萘基和酰苯胺取代的磺酰胺 | |
CN1076689A (zh) | 从羟基胺衍生的n,n′-取代亚胺二碳亚胺二酰胺 | |
CN1161120C (zh) | 多环2-氨基噻唑体系在预防或治疗肥胖的药物制备中的用途 | |
CN1263734C (zh) | 酰基-3-羧基苯基脲衍生物、其制备方法及其应用 | |
CN1181818C (zh) | 治疗原虫感染的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1065027 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: AVENTIS PHARMA GMBH Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
CP01 | Change in the name or title of a patent holder |
Address after: Frankfurt, Germany Patentee after: Sanofi-Aventis Deutschland GmbH Address before: Frankfurt, Germany Patentee before: Aventis Pharma Deutschland GmbH |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |